Focused ultrasound, proven across the world
Haifu technology has treated hundreds of thousands of patients globally, with clinical use across more than 36 countries and regions. This page documents the evidence behind the technology, distinguishing manufacturer-reported deployment from peer-reviewed research.
LETS EXPLORE THE TECHNOLOGY TIMELINE BELOW
1999
Haifu System 001 enters clinical practice
2002
Haifu system exported to University of Oxford
2010
JC200 deployment documented internationally
2015
JC200 introduced at Chris Hani Baragwanath — Africa's first according to Haifu
2020
JC300 globally launched
2023
First JC300 overseas export to Tanzania
2025
Haifu reports 36 countries/regions and ~350,000 patients
2026
Focused ultrasound deployment progresses in South Africa's private sector (manufacturer confirmation required for specific details).
Global HIFU Experience
Manufacturer-reported deployment. Source: Chongqing Haifu Medical Technology Co., Ltd. Figures are manufacturer-reported and cover the broader Haifu HIFU technology portfolio, not the JC300 alone.
36+
Countries & Regions With Haifu Machines
360 000
Patients Treated Worldwide
3000+
Physician's Trained
135
Countries & regions represented in training of physicans
PUBLISHED HIFU EVIDENCE
These figures represent different evidence reviews and should not be added together.
60
Uterine Fribroids
Studies included in a 2024 systematic review of HIFU safety for uterine fibroids.
5,216
Long-Term Reintervention
Patients included across 18 studies evaluating long-term HIFU reintervention outcomes.
4,450
Improvement in Fibroid Related Symptoms
Women included in a meta-analysis comparing HIFU with surgical treatment for symptomatic uterine fibroids.
2,622
31 Randomized Control Trials
Participants included in a 2026 network meta-analysis of minimally invasive interventions for symptomatic uterine fibroids.
Safety evidence
Major adverse events were rare in the included review data, with zero deaths reported across the studies analysed.
38%
lower abdominal pain in the pooled data analysed for that outcome
0.6%
skin burns/blisters/nodules
14.7%
abnormal vaginal discharge
1.7%
vaginal bleeding